Exact Mass: 712.4034

Exact Mass Matches: 712.4034

Found 31 metabolites which its exact mass value is equals to given mass value 712.4034, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

PA(14:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

[(2R)-3-[(9Z)-tetradec-9-enoyloxy]-2-{[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C37H61O11P (712.3951)


PA(14:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of Lipoxin A5 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/14:1(9Z))

[(2R)-2-[(9Z)-tetradec-9-enoyloxy]-3-{[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxy}propoxy]phosphonic acid

C37H61O11P (712.3951)


PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/14:1(9Z)), in particular, consists of one chain of one Lipoxin A5 at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

3beta-[7-((S)-1-Carboxy-4-guanidino-butylcarbamoyl)-heptanoyloxy]-14,15beta-epoxy-5-hydroxy-5beta,14beta-bufa-20,22-dienolid|3beta-[7-((S)-1-carboxy-4-guanidino-butylcarbamoyl)-heptanoyloxy]-14,15beta-epoxy-5-hydroxy-5beta,14beta-bufa-20,22-dienolide|marinobufotoxin

3beta-[7-((S)-1-Carboxy-4-guanidino-butylcarbamoyl)-heptanoyloxy]-14,15beta-epoxy-5-hydroxy-5beta,14beta-bufa-20,22-dienolid|3beta-[7-((S)-1-carboxy-4-guanidino-butylcarbamoyl)-heptanoyloxy]-14,15beta-epoxy-5-hydroxy-5beta,14beta-bufa-20,22-dienolide|marinobufotoxin

C38H56N4O9 (712.4047)


   

(25R)-3-O-(2-hydroxybutyryl)-5alpha-spirostane-2alpha,3beta,5,6beta-tetrol 2-O-beta-D-glucopyranoside

(25R)-3-O-(2-hydroxybutyryl)-5alpha-spirostane-2alpha,3beta,5,6beta-tetrol 2-O-beta-D-glucopyranoside

C37H60O13 (712.4034)


   

Dihydroxy tomatidine-O-hexosyl-O-pentoside

Dihydroxy tomatidine-O-hexosyl-O-pentoside

C37H60O13 (712.4034)


   

2alpha-Hydroxymaprounic acid 2,3-bis-p-hydroxybenzoate

2alpha-Hydroxymaprounic acid 2,3-bis-p-hydroxybenzoate

C44H56O8 (712.3975)


A pentacyclic triterpenoid that is the diester obtained by the condensation of the hydroxy groups of 2alpha-hydroxymaprounic acid with p-hydroxybenzoic acid. Isolated from Maprounea africana, it exhibits inhibitory activity against HIV-1 reverse transcriptase.

   

PA(14:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

PA(14:1(9Z)/20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15))

C37H61O11P (712.3951)


   

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/14:1(9Z))

PA(20:5(7Z,9Z,11E,13E,17Z)-3OH(5,6,15)/14:1(9Z))

C37H61O11P (712.3951)


   
   

[1-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C41H61O8P (712.4104)


   

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C41H61O8P (712.4104)


   

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C41H61O8P (712.4104)


   

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

C41H61O8P (712.4104)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C41H61O8P (712.4104)


   
   
   

PA 14:1/20:5;O3

PA 14:1/20:5;O3

C37H61O11P (712.3951)


   

PA 22:4/12:2;O3

PA 22:4/12:2;O3

C37H61O11P (712.3951)


   
   
   
   

PG P-18:1/13:5;O2

PG P-18:1/13:5;O2

C37H61O11P (712.3951)


   
   
   
   
   
   
   

(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,15'r,16'r,18'r,19'r)-18',19'-dihydroxy-5,7',9',13'-tetramethyl-15'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-yl (2r)-2-hydroxybutanoate

(1's,2r,2's,4's,5r,7's,8'r,9's,12's,13'r,15'r,16'r,18'r,19'r)-18',19'-dihydroxy-5,7',9',13'-tetramethyl-15'-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-yl (2r)-2-hydroxybutanoate

C37H60O13 (712.4034)


   

18',19'-dihydroxy-5,7',9',13'-tetramethyl-15'-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-yl 2-hydroxybutanoate

18',19'-dihydroxy-5,7',9',13'-tetramethyl-15'-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-16'-yl 2-hydroxybutanoate

C37H60O13 (712.4034)


   

(2s)-5-carbamimidamido-2-[(1-hydroxy-8-{[(1r,2s,4r,6r,7r,10s,11r,14s,16s)-16-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-8-oxooctylidene)amino]pentanoic acid

(2s)-5-carbamimidamido-2-[(1-hydroxy-8-{[(1r,2s,4r,6r,7r,10s,11r,14s,16s)-16-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-8-oxooctylidene)amino]pentanoic acid

C38H56N4O9 (712.4047)